ArticleNeuro-oncology practice2017
Palliative and end-of-life care in glioblastoma: defining and measuring opportunities to improve care.
Article in Neuro-oncology practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Palliative care in glioblastoma patients: a systematic review.Revista da Associacao Medica Brasileira (1992) · 2024Pooled it
- Palliative care and end-of-life care in adults with malignant brain tumors.Neuro-oncology · 2023Pooled it
- Neuropalliative care in brain cancer.Clinical medicine (London, England) · 2026Review
- Retrospective Characterization of Specialized Palliative Care in Patients With Gliomas.Journal of the advanced practitioner in oncology · 2026Article
- Outcomes of inpatient chemoradiotherapy for patients with newly diagnosed glioblastoma and significant functional impairment.Neuro-oncology practice · 2026Article
- Patterns and quality of therapeutic care for glioma: a population-based study in Belgium between 2016 and 2019.ESMO open · 2026Article
- Review
- Early Palliative Care in Patients with Glioblastoma: Co-Design of an Integrated Care Pathway.Healthcare (Basel, Switzerland) · 2025Article
- End-of-life care in glioblastoma: A population-based study.Neuro-oncology · 2025Article
- Biomarkers in glioblastoma and degenerative CNS diseases: defining new advances in clinical usefulness and therapeutic molecular target.Frontiers in molecular biosciences · 2025Article
- Benchmarking palliative care practices in neurooncology: a german perspective.Journal of neuro-oncology · 2024Article
- Clinical Feature Ranking Based on Ensemble Machine Learning Reveals Top Survival Factors for Glioblastoma Multiforme.Journal of healthcare informatics research · 2024Article
- Patient feasibility as a novel approach for integrating IRT and LCA statistical models into patient-centric qualitative data-a pilot study.Frontiers in digital health · 2024Article
- Effect of palliative care decisions making on hospital service use at end-of-life in patients with malignant brain tumors: a retrospective study.BMC palliative care · 2023Article
- A retrospective chart review to identify the involvement of palliative care with glioblastoma multiforme patients.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2023Article
- Article
- Supportive care of neurodegenerative patients.Frontiers in oncology · 2023Review
- Practical guidance for telemedicine use in neuro-oncology.Neuro-oncology practice · 2022Review
- Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas: A Retrospective Observational Study.Neurology · 2022Observational
- Palliative Care Service Utilization and Advance Care Planning for Adult Glioblastoma Patients: A Systematic Review.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmerican Society for Clinical Oncology (ASCO) quality measures for terminal cancers recommend early advance care planning and hospice at the end of life. We sought to evaluate adherence to 5 palliative care quality measures and explore associations with patient outcomes in glioblastoma.
methodsThis is a retrospective analysis of 117 deceased glioblastoma patients over 5 years. Records were reviewed to describe adherence to palliative care quality measures and patient outcomes. Data regarding emotional assessments, advance directives, palliative care consultation, chemotherapy administration, hospice, location of death, and overall survival were collected.
resultsMedian overall survival was 12.9 months. By the second oncology visit, 22.2% (26/117) had an emotional assessment completed. Advance directives were documented for 52.1% (61/117) by the third neuro-oncology visit (30/61 health care proxy), yet 26.5% (31/117) did not have any advance directive before the last month of life. With regard to other ASCO quality measures, 36.8% (43/117) had a palliative care consult; 94.0% (110/117) did not receive chemotherapy in the last 14 days of life; 59.8% (70/117) enrolled in hospice >7 days before death; and 56.4% (66/117) died in a home setting. Patients who enrolled in hospice >7 days before death were 3.56 times more likely to die in a home setting than patients enrolled <7 days before death or with no hospice enrollment (
conclusionsLate advance directive documentation, minimal early palliative care involvement, and the association of early hospice enrollment with death in a home setting underscore the need to improve care and better define palliative care quality measures in glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.